Janssen gets FDA approval for Invokana to reduce risk of CV events

31 October 2018 (Last Updated October 31st, 2018 11:32)

Janssen Pharmaceutical has received approval from the US Food and Drug Administration (FDA) for the use of Invokana (canagliflozin) to minimise the risk of major adverse cardiovascular (CV) events in adults.

Janssen gets FDA approval for Invokana to reduce risk of CV events
Janssen’s Invokana is an oral medicine indicated to decrease blood sugar in type 2 diabetes patients. Credit: Bic.

Janssen Pharmaceutical has received approval from the US Food and Drug Administration (FDA) for the use of Invokana (canagliflozin) to minimise the risk of major adverse cardiovascular (CV) events in adults.

The indication covers CV events such as heart attack, stroke or death in patients with type 2 diabetes (T2D) and have a known CV condition.

Invokana is an oral, prescription medicine to decrease blood sugar (glucose) in adults with T2D. The drug must be used along with diet and exercise.

Janssen said that the FDA decision comes after the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE) released reports supporting Invokana use.

“This FDA approval makes Invokana the only oral type 2 diabetes treatment indicated to reduce the risk of heart attack, stroke or CV death.”

Janssen Research & Development cardiovascular and metabolism global therapeutic area head James List said: “This FDA approval makes Invokana the only oral type 2 diabetes treatment indicated to reduce the risk of heart attack, stroke or CV death.

“Not only does Invokana enable patients to control their diabetes symptoms by lowering their A1C levels, but it now also helps protect them from potentially devastating cardiovascular events.”

Invokana’s effect on CV risk was assessed in the CANVAS Program that involved a total of more than 10,000 adults with T2D and established CV disease or at risk for the disease with two or more risk factors.

Overall data showed that the drug in combination with standard of care led to a 14% decrease in the combined risk of heart attack, stroke and CV death, compared to placebo.

For participants with established CV disease, Invokana reduced the combined risk of heart attack, stroke and CV death by 18%.